

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**ASTRAZENECA PHARMACEUTICALS LP**

2. Address:

1800 CONCORD PIKE, P.O. BOX 15437, WILMINGTON, DE 19850-5437

3. Principal place of business (if different from line 2):

4. Contact Name: THOMAS F. FELTON

Telephone: 3028854873

E-mail (optional): thomas.felton@astrazeneca.com

Senate ID #: 54073-12

House ID #:

7. Client Name:  Self

## TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: \_\_\_\_\_ 11. No Lobbying Activity:

## INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): \_\_\_\_\_

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): 1,700,000.00

### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

**Method A.** Reporting amounts using LDA definitions only

**Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

**Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

S.1145/1908 The Patent Reform Act of 2007 - Potential implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUCKLEY, RICHARD

Covered Official Position (if applicable): N/A

Name: IZQUIERDO, ANDREW

Covered Official Position (if applicable): N/A

Name: MOTT, AMANDA

Covered Official Position (if applicable): N/A

Name: OLSON, RICHARD

Covered Official Position (if applicable): N/A

Name: PALMER, WAYNE

Covered Official Position (if applicable): N/A

Name: ROSSIN, BRADLEY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CSP (one per page)

16. Specific lobbying issues:

Patient safety from the commercial importation of prescription medications Manufacturer outsourcing of active pharmaceutical ingredients to certain countries

17. House(s) of Congress and Federal agencies contacted:  
HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUCKLEY, RICHARD  
Covered Official Position (if applicable): N/A

Name: IZQUIERDO, ANDREW  
Covered Official Position (if applicable): N/A

Name: MOTT, AMANDA  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

S.1082 FDARA - reauthorization and funding of FDA and PDUFA-related issues HR 2900 FDAAA - reauthorization and funding of FDA and PDUFA-related issues HR 3610 Food & Drug Safety Act of 2007 - reauthorization and funding of FDA and PDUFA-related issues S. 1859/HR 3161 - Ag, Rural Dev, FDAAdministration & Related Agencies Approp Act of 2008 - reauth and funding of FDA

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUCKLEY, RICHARD

Covered Official Position (if applicable): N/A

Name: IZQUIERDO, ANDREW

Covered Official Position (if applicable): N/A

Name: MCRAE, DEANA

Covered Official Position (if applicable): N/A

Name: OLSON, RICHARD

Covered Official Position (if applicable): N/A

Name: PALMER, WAYNE

Covered Official Position (if applicable): N/A

Name: ROSSIN, BRADLEY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Proposed increase in Medicaid Drug Rebate drug base rebate increase Proposed changes to Medicaid price reporting and requirements from earlier legislation (DRA) Medicare Part D formulary protection for six specified classes

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: IZQUIERDO, ANDREW

Covered Official Position (if applicable): N/A

Name: MOTT, AMANDA

Covered Official Position (if applicable): N/A

Name: OLSON, RICHARD

Covered Official Position (if applicable): N/A

Name: PALMER, WAYNE

Covered Official Position (if applicable): N/A

Name: ROSSIN, BRADLEY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

**LOBBYING ACTIVITY.**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

Illegal compounding of commercially available pharmaceuticals by pharmacists

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ROSSIN, BRADLEY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ASTRAZENECA PHARMACEUTICALS LP Client Name: Self

**LOBBYING ACTIVITY**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TAX (one per page)

16. Specific lobbying issues:

Renewal of Research and Development Tax Credit within context of proposed changes to Alternative Minimum Tax

17. House(s) of Congress and Federal agencies contacted:

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: PALMER, WAYNE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Feb 14, 2008

Printed Name and Title: THOMAS F. FELTON, COUNSEL -

**Information Update Page:**

**Complete ONLY where registration information has changed.**

**LOBBYIST UPDATE**

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

Name: MCRAE, DEANA

**ISSUE UPDATE**

**24. General lobbying issues previously reported that NO LONGER pertain**

**AFFILIATED ORGANIZATIONS**

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

**FOREIGN ENTITIES**

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE Date: Feb 14, 2008

Printed Name and Title: -